Cognetivity Neurosciences Publishes Outstanding Results and Expands Deployment With Senior Care Network in Singapore
Cognetivity Neurosciences Publishes Outstanding Results and Expands Deployment With Senior Care Network in Singapore
Expansion of first-phase deployment follows excellent published results, showing cross-cultural validity, leading to further expansion and market traction in Asia
在第一階段部署的擴大之前，公佈了出色的結果，顯示了跨文化的有效性，導致在亞洲進一步擴大規模和市場吸引力
Vancouver, British Columbia--(Newsfile Corp. - March 8, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity"), a technology company that has created a unique brain health screening platform for use in medical, commercial and consumer environments, is pleased to announce that it is extending the deployment of its CognICA technology with Lions Befrienders Service Association ("Lions Befrienders" or "LBSA"), a leading Singapore-based senior healthcare provider.
溫哥華，不列顛哥倫比亞省-(Newsfile Corp.-2023年3月8日)-認知神經科學有限公司(CSE：CGN)(OTCQB：CGNSF)(FSE：1UB)(“公司”或“認知”)，一家創建了用於醫療、商業和消費環境的獨特腦健康篩查平臺的科技公司高興地宣佈，它將與獅子山服務協會(Lions Befriders Service Association)一起擴展其CognICA技術的部署。獅子Befriers“或”LBSA“)，一家總部位於新加坡的領先的高級醫療保健提供商。
Established in 1995, Lions Befrienders has addressed the varied needs of more than 86,000 senior citizens across Singapore via a spectrum of integrated eldercare services from preventive to intervention through comprehensive programmes, including social, emotional, mental and physical rehabilitation. LBSA's initiative is backed by major pharmaceutical companies including Abbott, GSK, Roche, Abbvie and MSD, is supported by over 1,500 regular volunteers.
獅子會成立於1995年，通過一系列綜合老年護理服務，從預防到幹預，通過全面的計劃，包括社會、情感、心理和身體康復，滿足了新加坡超過86,000名老年人的不同需求。LBSA的倡議得到了包括雅培、葛蘭素史克、羅氏、艾伯維和MSD在內的主要製藥公司的支持，並得到了1500多名常規志願者的支持。
Cognetivity has entered into an agreement with Lions befrienders that delivers assessment of cognitive development within this seniors population in Singapore. The project has been designed into two phases, the first, now completed, assessed 250 individuals over a period of 3 months, with phase two seeing the expansion of testing to 1,250 senior citizens. The initial deployment started in June 2022 and saw Cognetivity's CognICA brain health screening platform used with a select group of seniors to identify, assess and evaluate those suffering from, or at risk of, cognitive impairment due to dementia. This generated excellent results from which Cognetivity has published a white paper which can be read here.
Cognetivity已經與獅子會達成了一項協定，對新加坡這一老年人群體的認知發展進行評估。該專案分為兩個階段，第一階段現已完成，在3個月的時間內對250人進行了評估，第二階段將測試擴大到1250名老年人。最初的部署始於2022年6月，Cognetivity的CognICA腦健康篩查平臺與一組精選的老年人一起使用，以識別、評估和評估那些因痴呆症而患有認知障礙或面臨認知障礙風險的人。這產生了出色的結果，Cognetivity發佈了一份白皮書，可以在這裡閱讀。
The results of the study demonstrated the effectiveness and usability of CognICA in screening and monitoring senior participants in the comfort of community settings across Singapore, rather than having to attend a medical clinic. The tool proved capable of highlighting those at risk of cognitive decline, and these were then followed up by LBSA's active aging program, providing early intervention before cognitive decline becomes severe.
這項研究的結果證明瞭CognICA在篩選和監測新加坡各地舒適的社區環境中的老年參與者方面的有效性和可用性，而不是不得不去醫療診所。事實證明，該工具能夠突出那些有認知能力下降風險的人，然後LBSA的主動老齡化計劃對這些人進行跟蹤，在認知能力下降變得嚴重之前提供早期幹預。
The use of CognICA allows the measurement of the effectiveness of LBSA's active aging programs, which showed a positive impact on the cognitive health of the seniors. The number of individuals highlighted as at-risk or impaired by CognICA were significantly reduced when re-assessed after completion of the intervention program and, in addition, feedback from the users showed a strong preference to being assessed at or close to home rather than in a hospital setting, as well as finding CognICA user-friendly and easy to use.
CognICA的使用可以衡量LBSA主動老齡化計劃的有效性，這對老年人的認知健康產生了積極影響。在幹預計劃完成後重新評估時，被CognICA突出顯示為高危或受損的個人數量顯著減少，此外，來自用戶的反饋顯示出強烈傾向於在家中或靠近家的地方而不是在醫院環境中進行評估，併發現CognICA用戶友好和易於使用。
This demonstrable effectiveness of the technology further evidences its cross-cultural performance and shows its ability to both detect brain health issues at an early stage and, importantly, its ability to be used as an ongoing monitoring tool to objectively measure the positive impact of treatment programs and interventions.
這項技術的這種明顯的有效性進一步證明瞭它的跨文化表現，並表明它有能力在早期階段發現大腦健康問題，更重要的是，它有能力被用作持續監測工具，客觀地衡量治療計劃和幹預措施的積極影響。
With the success observed in phase one of the deployment, CGN and Lions Befrienders have agreed to proceed to the next phase of the engagement. With the ongoing support of the large pharmaceutical companies funding the project and with the support from the Singapore Ministry of Health (MoH), Lions Befrienders plan to expand the service to 1250 seniors within their care. This project is now being observed by the MoH in Singapore and this success moves closer to the replication of this approach across all the integrated care networks of the MoH, towards a national screening program in advance of new disease treating drugs coming to market for conditions such as Alzheimer's.
隨著在第一階段的部署中觀察到的成功，中廣核和獅子山已同意繼續進行下一階段的接觸。在資助該專案的大型製藥公司的持續支持下，在新加坡衛生部(MoH)的支持下，獅子會計劃將這項服務擴大到他們護理的1250名老年人。新加坡衛生部正在觀察這一項目，這一成功離在衛生部所有綜合護理網路中複製這一方法又近了一步，朝著在治療阿爾茨海默氏症等疾病的新疾病藥物上市之前進行全國篩查計劃邁進了一步。
"We are delighted to share the results from this very successful deployment with Lions Befrienders in Singapore. The positive feedback both from a scientific and an end-user perspective from this, and the expansion of the program is great confirmation of the power of our CognICA platform in helping deliver the best possible care to people wherever they are in the world." said Dr. Sina Habibi, Chief Executive Officer of Cognetivity. "Successful deployment of our technology to APAC shows huge global scalability of the solution in a variety of use cases within and outside clinics, enabling mass scale screening at speed. We're extremely excited with the role that CognICA will play in helping millions of people live longer and fuller lives globally."
我們很高興在新加坡與Lions Befriders分享這一非常成功的部署結果。從科學和最終用戶的角度來看，這方面的積極反饋以及該計劃的擴大極大地證實了我們的CognICA平臺在幫助世界各地的人們提供盡可能好的護理方面的力量。Cognetivity首席執行官Sina Habibi博士說。我們的技術在亞太地區的成功部署表明，該解決方案在診所內外的各種用例中具有巨大的全球可擴展性，能夠快速進行大規模篩查。我們對CognICA將在幫助全球數百萬人活得更長、更充實的生活中發揮的作用感到非常興奮。“
According to the Lancet Commission, almost one billion people worldwide suffer from a mental disorder and the estimated costs of these disorders is estimated to have a global economic cost of US$16 trillion by 2030. Early detection of brain health disorders has the potential to significantly reduce costs of care while improving patient outcomes. Cognetivity's CognICA technology is a unique and highly scalable software-as-a-service solution able to accurately detect the earliest stages of the majority of major brain health disorders.
根據柳葉刀委員會的數據，全球近10億人患有精神障礙，到2030年，這些疾病的估計成本估計將使全球經濟損失16萬億美元。早期發現大腦健康障礙有可能顯著降低護理成本，同時改善患者預後。Cognetivity的CognICA技術是一種獨特的、高度可擴展的軟體即服務解決方案，能夠準確地檢測大多數主要大腦健康疾病的早期階段。
About Cognetivity Neurosciences Ltd.
關於認知性神經科學有限公司
Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity's ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of cognitive impairment by testing the performance of large areas of the brain. The ICA is currently available for clinical use in the USA, UK, Europe and the Middle East, with regulatory approval for other regions planned for 2023.
Cognetivity是一家技術公司，它創建了一個認知測試平臺，用於醫療、商業和消費環境。Cognetivity的ICA使用人工智慧和機器學習技術，通過測試大腦大片區域的表現來幫助檢測認知障礙的最早跡象。ICA目前可在美國、英國、歐洲和中東用於臨床，其他地區的監管批准計劃於2023年進行。
ON BEHALF OF THE BOARD
我代表董事會
"Sina Habibi"
Sina Habibi
《新浪哈比比》
新浪哈比比
Chief Executive Officer and Director
董事首席執行官兼首席執行官
FORWARD-LOOKING STATEMENTS:
前瞻性陳述：
Certain statements included in this news release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "assume" "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This news release contains forward looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Such statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company's forward-looking statements.
本新聞稿中包含的某些陳述構成前瞻性資訊或陳述(統稱為“前瞻性陳述”)，包括“預期”、“假設”、“相信”、“計劃”、“估計”、“預期”、“打算”、“可能”、“應該”以及與公司或其管理層有關的類似表述。前瞻性陳述不是歷史事實，但反映了對未來結果或事件的當前預期。本新聞稿包含前瞻性陳述。這些前瞻性陳述不是對未來業績的保證，涉及難以預測的風險、不確定因素和假設。此類陳述基於當前預期和各種估計、因素和假設，涉及已知和未知的風險、不確定性和其他因素。這些陳述和資訊是基於對目前和未來的業務戰略以及公司未來運營環境的許多假設。除非法律要求，否則公司不承擔更新或修改前瞻性資訊以反映新事件或新情況的責任。讀者不應過分依賴該公司的前瞻性陳述。
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
加拿大證券交易所不對本新聞稿的充分性或準確性承擔責任。
For further information: Please visit: or contact: info@cognetivity.com; for media inquiries please contact pr@cognetivity.com.
有關更多資訊，請訪問：請訪問：或聯繫：info@cognetivity.com；媒體查詢請聯繫pr@cognetivity.com。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。